Browsing by Subject "Survival time"
Now showing items 21-32 of 32
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
(2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...
-
Article
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
(1997)We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent ...
-
Article
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety
(2006)Patients with metastatic breast cancer receive multiple lines of cytotoxic chemotherapy, with taxane and anthracycline-based regimens being the most active. Anthracyclines carry the risk of significant cardiotoxicity at ...
-
Article
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
(2005)The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. ...
-
Article
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer
(2003)The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/ mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty ...
-
Article
-
Article
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: A study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
(2013)Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 ...
-
Article
Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary
(2015)Background: Cancer of unknown primary (CUP) possesses distinct biology and peculiar natural history, in which the roles of the winged and hedgehog signalling pathways are unclear. Materials and methods: We constructed ...
-
Article
Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature
(2013)Background: CUP represents a heterogeneous population of patients with systemic malignancy and variable outcomes. Identification of clinical, pathologic and laboratory parameters with prognostic utility could contribute ...
-
Article
Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma
(1996)The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals ...
-
Article
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
(2007)Background: Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental ...
-
Article
Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments
(2006)Background: Numerous randomized trials have compared different chemotherapy regimens in women with ovarian cancer. Although ovarian cancer survival has improved in recent years, the magnitude of these incremental benefits ...